Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea
The Korean Journal of Internal Medicine
; : 890-899, 2017.
Article
在 En
| WPRIM
| ID: wpr-151260
Responsible library:
WPRO
ABSTRACT
BACKGROUND/AIMS:
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy that typically presents in the form of skin manifestations with or without lymph node and bone marrow involvement. Given its rarity and recent recognition as a distinct pathological entity, no standard of treatment exists for this aggressive disease and its prognosis is particularly dismal.METHODS:
We retrospectively analyzed clinical features and treatment outcomes of patients who were diagnosed with BPDCN between 2000 and 2014.RESULTS:
Ten patients had a median age at diagnosis of 41 years (range, 18 to 79), and seven patients were male. Sites of disease involvement were the skin (n = 7), lymph node (n = 5), bone marrow (n = 2), liver (n = 2), spleen (n = 2), and soft tissue (n = 1). Intensified chemotherapy regimens such as hyperCVAD regimen (cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine), and VPDL (vincristine, methylprednisolone, daunorubicin, L-asparaginase) were used as a first-line treatment. Although all patients treated with intensified chemotherapy showed an objective response (five patients with complete response) with median progression-free survival of 11.2 months (range 6.2 to 19.4), complete remission was not sustained for more than 2 years in any case. The response was relatively long-lived compared with previously reported CHOP (doxorubicin, cyclophosphamide, vincristine, prednisone)-like regimens, but the above regimens do not result in long-term remission.CONCLUSIONS:
All patients treated with hyperCVAD or VPDL showed an objective response, but the duration of response was relatively short. Thus, the development of more effective induction as well as consolidation treatment strategy should be warranted to improve this rare disease entity.Key words
全文:
1
索引:
WPRIM
主要主题:
Prognosis
/
Skin
/
Skin Manifestations
/
Spleen
/
Vincristine
/
Bone Marrow
/
Dendritic Cells
/
Dexamethasone
/
Methylprednisolone
/
Daunorubicin
研究类型:
Diagnostic_studies
/
Observational_studies
/
Prognostic_studies
限制:
Humans
/
Male
国家/地区名称主题:
Asia
语言:
En
期刊:
The Korean Journal of Internal Medicine
年:
2017
类型:
Article